{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:32:37Z","timestamp":1779323557066,"version":"3.51.4"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T00:00:00Z","timestamp":1545350400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T00:00:00Z","timestamp":1545350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1111\/jcpt.12781","type":"journal-article","created":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T04:10:37Z","timestamp":1545451837000},"page":"249-257","source":"Crossref","is-referenced-by-count":11,"title":["The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma"],"prefix":"10.1155","volume":"44","author":[{"given":"Eveline S.","family":"Mense","sequence":"first","affiliation":[{"name":"Department of Pharmacy; OLVG Hospital; Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur A. J.","family":"Smit","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine; OLVG Hospital; Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjam","family":"Crul","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy; Amsterdam University Medical Center; Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J. F.","family":"Franssen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; OLVG Hospital; Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,12,21]]},"reference":[{"issue":"Suppl 5","key":"10.1111\/jcpt.12781-BIB0001|jcpt12781-cit-0001","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","article-title":"Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Novello","year":"2016","journal-title":"Ann Oncol"},{"issue":"Suppl 6","key":"10.1111\/jcpt.12781-BIB0002|jcpt12781-cit-0002","doi-asserted-by":"crossref","first-page":"vi89","DOI":"10.1093\/annonc\/mdt241","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Vansteenkiste","year":"2013","journal-title":"Ann Oncol"},{"issue":"Suppl 6","key":"10.1111\/jcpt.12781-BIB0003|jcpt12781-cit-0003","doi-asserted-by":"crossref","first-page":"vi99","DOI":"10.1093\/annonc\/mdt178","article-title":"Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Fruh","year":"2013","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1111\/jcpt.12781-BIB0004|jcpt12781-cit-0004","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1111\/jcpt.12781-BIB0005|jcpt12781-cit-0005","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s11096-013-9912-7","article-title":"Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow?","volume":"36","author":"Bennis","year":"2014","journal-title":"Int J Clin Pharm"},{"key":"10.1111\/jcpt.12781-BIB0006|jcpt12781-cit-0006","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000086055","article-title":"Cisplatin-associated nephrotoxicity and pathological events","volume":"148","author":"Taguchi","year":"2005","journal-title":"Contrib Nephrol"},{"issue":"5","key":"10.1111\/jcpt.12781-BIB0007|jcpt12781-cit-0007","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0270-9295(03)00089-5","article-title":"Cisplatin nephrotoxicity","volume":"23","author":"Arany","year":"2003","journal-title":"Semin Nephrol"},{"issue":"11","key":"10.1111\/jcpt.12781-BIB0008|jcpt12781-cit-0008","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of Cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins"},{"issue":"9","key":"10.1111\/jcpt.12781-BIB0009|jcpt12781-cit-0009","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.ki.5002786","article-title":"Cisplatin nephrotoxicity: mechanisms and renoprotective strategies","volume":"73","author":"Pabla","year":"2008","journal-title":"Kidney Int"},{"issue":"1","key":"10.1111\/jcpt.12781-BIB0010|jcpt12781-cit-0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40620-017-0392-z","article-title":"Cisplatin nephrotoxicity: a review of the literature","volume":"31","author":"Manohar","year":"2018","journal-title":"J Nephrol"},{"issue":"5","key":"10.1111\/jcpt.12781-BIB0011|jcpt12781-cit-0011","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","article-title":"A systematic review of strategies to prevent cisplatin-induced nephrotoxicity","volume":"22","author":"Crona","year":"2017","journal-title":"Oncologist"},{"key":"10.1111\/jcpt.12781-BIB0012|jcpt12781-cit-0012","unstructured":"Bristol-Myers Squibb Platinol - FDA Prescribing Information, side effects and uses 2010 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/018057s080lbl.pdf"},{"issue":"7","key":"10.1111\/jcpt.12781-BIB0013|jcpt12781-cit-0013","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s004670100610","article-title":"Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions","volume":"16","author":"Erdlenbruch","year":"2001","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"10.1111\/jcpt.12781-BIB0014|jcpt12781-cit-0014","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0090-8258(89)80033-2","article-title":"A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study","volume":"32","author":"Thigpen","year":"1989","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1111\/jcpt.12781-BIB0015|jcpt12781-cit-0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1006\/gyno.1995.1267","article-title":"Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva","volume":"59","author":"Eifel","year":"1995","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1111\/jcpt.12781-BIB0016|jcpt12781-cit-0016","first-page":"1409","article-title":"Safe, rapid administration of cisplatin in the outpatient clinic","volume":"70","author":"Brock","year":"1986","journal-title":"Cancer Treat Rep"},{"issue":"4","key":"10.1111\/jcpt.12781-BIB0017|jcpt12781-cit-0017","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.1985.3.4.559","article-title":"The effect of administration rate on cisplatin-induced emesis","volume":"3","author":"Jordan","year":"1985","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1111\/jcpt.12781-BIB0018|jcpt12781-cit-0018","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00280-003-0620-1","article-title":"Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial","volume":"52","author":"Santoso","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1111\/jcpt.12781-BIB0019|jcpt12781-cit-0019","first-page":"30","article-title":"A short outpatient hydration schedule for cisplatin administration","volume":"5","author":"Al Bahrani","year":"2009","journal-title":"Gulf J Oncolog"},{"issue":"2","key":"10.1111\/jcpt.12781-BIB0020|jcpt12781-cit-0020","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.1987.5.2.304","article-title":"Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity","volume":"5","author":"Reece","year":"1987","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1111\/jcpt.12781-BIB0021|jcpt12781-cit-0021","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00000421-198502000-00052","article-title":"Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations","volume":"8","author":"Kelsen","year":"1985","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1111\/jcpt.12781-BIB0022|jcpt12781-cit-0022","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/j.1875-9114.1997.tb03088.x","article-title":"Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors","volume":"17","author":"Lagrange","year":"1997","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1111\/jcpt.12781-BIB0023|jcpt12781-cit-0023","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/jjco\/28.3.168","article-title":"Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration","volume":"28","author":"Ikeda","year":"1998","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"10.1111\/jcpt.12781-BIB0024|jcpt12781-cit-0024","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"issue":"1","key":"10.1111\/jcpt.12781-BIB0025|jcpt12781-cit-0025","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1186\/s12885-017-3705-7","article-title":"Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed","volume":"17","author":"Assayag","year":"2017","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1111\/jcpt.12781-BIB0026|jcpt12781-cit-0026","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2015.05.005","article-title":"Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting","volume":"89","author":"Sassier","year":"2015","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1111\/jcpt.12781-BIB0027|jcpt12781-cit-0027","doi-asserted-by":"crossref","first-page":"43","DOI":"10.15171\/jnp.2017.07","article-title":"Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review","volume":"6","author":"Zattera","year":"2017","journal-title":"J Nephropathol"},{"issue":"3","key":"10.1111\/jcpt.12781-BIB0028|jcpt12781-cit-0028","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1385\/MO:23:3:419","article-title":"Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer","volume":"23","author":"Vootukuru","year":"2006","journal-title":"Med Oncol"},{"issue":"23","key":"10.1111\/jcpt.12781-BIB0029|jcpt12781-cit-0029","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","article-title":"PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer","volume":"31","author":"Paz-Ares","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1111\/jcpt.12781-BIB0030|jcpt12781-cit-0030","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00280-003-0574-3","article-title":"Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment","volume":"51","author":"Kiani","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1111\/jcpt.12781-BIB0031|jcpt12781-cit-0031","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/annonc\/mdh008","article-title":"Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis","volume":"15","author":"Inoue","year":"2004","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1111\/jcpt.12781-BIB0032|jcpt12781-cit-0032","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0002-9343(78)90825-2","article-title":"Platinum nephrotoxicity","volume":"65","author":"Madias","year":"1978","journal-title":"Am J Med"},{"issue":"4","key":"10.1111\/jcpt.12781-BIB0033|jcpt12781-cit-0033","doi-asserted-by":"crossref","first-page":"332","DOI":"10.5935\/0101-2800.20130052","article-title":"Acute nephrotoxicity of cisplatin: molecular mechanisms","volume":"35","author":"Peres","year":"2013","journal-title":"J Bras Nefrol"},{"issue":"4","key":"10.1111\/jcpt.12781-BIB0034|jcpt12781-cit-0034","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis","volume":"139","author":"Jafar","year":"2003","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1111\/jcpt.12781-BIB0035|jcpt12781-cit-0035","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/archinte.1995.00430100105012","article-title":"Long-term effects of antihypertensive agents on proteinuria and renal function","volume":"155","author":"Maki","year":"1995","journal-title":"Arch Intern Med"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12781","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12781\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T15:39:32Z","timestamp":1720885172000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,21]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12781","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,21]]}}}